<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CONTEXT: Given the higher risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defining <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> that include Kaposi <z:hpo ids='HP_0100242'>sarcoma</z:hpo> (KS), certain non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHLs), and <z:e sem="disease" ids="C0302592" disease_type="Neoplastic Process" abbrv="">cervical cancer</z:e> in persons with human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus (HIV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, the HIV epidemic has likely contributed to the overall numbers of these <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in the United States </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: To quantify the proportions of KS, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defining NHLs, and <z:e sem="disease" ids="C0302592" disease_type="Neoplastic Process" abbrv="">cervical cancer</z:e> in the United States that occurred among persons with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> from 1980 to 2007 </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN, SETTING, AND PARTICIPANTS: The HIV/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Match Study (1980-2007) linked data from 16 US HIV/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registries to identify cases with and without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> for KS, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defining NHLs (ie, diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>], Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>], and central <z:mp ids='MP_0008912'>nervous</z:mp> system [<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>] <z:hpo ids='HP_0002665'>lymphoma</z:hpo>), and <z:e sem="disease" ids="C0302592" disease_type="Neoplastic Process" abbrv="">cervical cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Using linked data, we derived <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> rates for persons with and without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>To estimate national counts, the rates were applied to national <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> surveillance and US Census data </plain></SENT>
<SENT sid="5" pm="."><plain>MAIN OUTCOME MEASURE: Proportion of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defining <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> in the United States occurring in persons with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: In the United States, an estimated 81.6% (95% confidence interval [CI], 81.2%-81.9%) of 83,252 KS cases, 6.0% (95% CI, 5.8%-6.1%) of 351,618 DLBCL cases, 19.9% (95% CI, 18.1%-21.7%) of 17,307 BL cases, 27.1% (95% CI, 26.1%-28.1%) of 27,265 CNS <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cases, and 0.42% (95% CI, 0.37%-0.47%) of 375,452 cervical <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cases occurred among persons with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> during 1980-2007 </plain></SENT>
<SENT sid="7" pm="."><plain>The proportion of KS and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defining NHLs in persons with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> peaked in the early 1990s (1990-1995: KS, 90.5% [95% CI, 90.2%-90.8%]; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, 10.2% [95% CI, 9.9%-10.5%]; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, 27.8% [95% CI, 25.0%-30.5%]; and <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 48.3% [95% CI, 46.7%-49.8%]; <z:hpo ids='HP_0000001'>all</z:hpo> P &lt; .001 [compared with 1980-1989]) and then declined (2001-2007: KS, 70.5% [95% CI, 68.1%-73.0%]; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, 4.7% [95% CI, 4.3%-5.2%]; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, 21.5% [95% CI, 17.7%-25.4%]; and <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 12.9% [95% CI, 10.5%-15.3%]; <z:hpo ids='HP_0000001'>all</z:hpo> P &lt; .001 [compared with 1990-1995]) </plain></SENT>
<SENT sid="8" pm="."><plain>The proportion of <z:e sem="disease" ids="C0302592" disease_type="Neoplastic Process" abbrv="">cervical cancers</z:e> in persons with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> increased over time (1980-1989: 0.11% [95% CI, 0.09%-0.13%]; 2001-2007: 0.71% [95% CI, 0.51%-0.91%]; P &lt; .001) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In the United States, the estimated proportions of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defining <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> that occurred among persons with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> were substantial, particularly for KS and some NHLs </plain></SENT>
<SENT sid="10" pm="."><plain>Except for <z:e sem="disease" ids="C0302592" disease_type="Neoplastic Process" abbrv="">cervical cancer</z:e>, the proportions of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-defining <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> occurring among persons with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> peaked in the mid-1990s and then declined </plain></SENT>
</text></document>